YM928

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562269

CAS#: 190842-36-5

Description: YM928 is an orally active AMPA receptor antagonist.


Chemical Structure

img
YM928
CAS# 190842-36-5

Theoretical Analysis

MedKoo Cat#: 562269
Name: YM928
CAS#: 190842-36-5
Chemical Formula: C14H10ClN3OS
Exact Mass: 303.0233
Molecular Weight: 303.76
Elemental Analysis: C, 55.36; H, 3.32; Cl, 11.67; N, 13.83; O, 5.27; S, 10.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YM928; YM-928; YM 928;

IUPAC/Chemical Name: 2-[(4-Chlorophenyl)(methyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one

InChi Key: RCGOQPBYNHJZCU-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10ClN3OS/c1-18(10-6-4-9(15)5-7-10)14-17-12(19)11-3-2-8-16-13(11)20-14/h2-8H,1H3

SMILES Code: O=C1N=C(N(C2=CC=C(Cl)C=C2)C)SC3=NC=CC=C13

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 303.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Inami H, Shishikura J, Yasunaga T, Ohno K, Yamashita H, Kato K, Sakamoto S. Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists. Bioorg Med Chem. 2015 Apr 15;23(8):1788-99. doi: 10.1016/j.bmc.2015.02.033. Epub 2015 Feb 25. PubMed PMID: 25792143.

2: Kato K, Noguchi K, Aoki T, Soeishi Y, Kamimura H. Simultaneous determination of YM928, a novel noncompetitive AMPA receptor antagonist, and its demethylated metabolite in rat, dog and monkey plasma by high-performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 2006 Dec;20(12):1328-35. PubMed PMID: 16977590.

3: Yamashita H, Ohno K, Amada Y, Inami H, Shishikura J, Sakamoto S, Okada M, Yamaguchi T. Effect of YM928, a novel AMPA receptor antagonist, on seizures in EL mice and kainate-induced seizures in rats. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):99-105. Epub 2004 Jul 31. PubMed PMID: 15322731.

4: Yamashita H, Ohno K, Inami H, Shishikura J, Sakamoto S, Okada M, Yamaguchi T. Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy. Eur J Pharmacol. 2004 Jun 28;494(2-3):147-54. PubMed PMID: 15212968.

5: Yamashita H, Ohno K, Amada Y, Hattori H, Ozawa-Funatsu Y, Toya T, Inami H, Shishikura J, Sakamoto S, Okada M, Yamaguchi T. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J Pharmacol Exp Ther. 2004 Jan;308(1):127-33. Epub 2003 Oct 20. PubMed PMID: 14569061.

6: Ohno K, Tsutsumi R, Matsumoto N, Yamashita H, Amada Y, Shishikura J, Yatsugi HI, Okada M, Sakamoto S, Yamaguchi T. Functional characterization of YM928, a novel moncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. J Pharmacol Exp Ther. 2003 Jul;306(1):66-72. Epub 2003 Mar 26. PubMed PMID: 12660313.